Qiagen Stock Price, News & Analysis

QIAGEN N.V. (NYSE: QGEN) has joined the "Business Ambition for 1.5˚C" campaign, committing to achieve net-zero carbon emissions by 2050. The company aims for a minimum of 40% reduction in Scope 1 and 2 emissions, and 10% in Scope 3 emissions by 2030 from a 2020 baseline. This initiative aligns with the Paris Climate Agreement and positions QIAGEN among over 2,000 global entities in the Race to Zero Campaign. QIAGEN is embedding environmental sustainability into operations, including using renewable energy and reducing packaging plastics.

QIAGEN N.V. (NYSE: QGEN) and Becton, Dickinson and Company (NYSE: BDX) have settled a patent infringement lawsuit concerning QIAGEN’s NeuMoDx™ PCR systems. The settlement, resolving all claims, mandates a one-time payment of $53 million to BD. Notably, this agreement does not alter QIAGEN's expected net sales or adjusted earnings outlook for Q4 and full-year 2021. QIAGEN continues to offer innovative solutions for molecular diagnostics.

QIAGEN N.V. reported an 11% increase in Q3 2021 net sales, reaching $535 million, with a significant growth of 17% in its non-COVID product sales. The company's adjusted diluted EPS remained stable at $0.58, exceeding market expectations. For the first nine months of 2021, net sales surged to $1.67 billion, marking a 28% increase, while operating cash flow nearly doubled. QIAGEN has upgraded its full-year outlook, anticipating at least 15% sales growth and an adjusted diluted EPS of at least $2.48.

QIAGEN announced the CE-marking and upcoming launch of the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test. This test differentiates between influenza A, B, RSV, and SARS-CoV-2, crucial for flu season diagnoses. It enhances QIAGEN's extensive portfolio of PCR solutions combatting COVID-19, delivering results in about an hour without sample preparation. The product's introduction responds to the urgent need for accurate diagnostics highlighted by the pandemic, facilitating informed therapeutic decisions and optimizing patient management.

QIAGEN has completed its relocation to the CityLabs 2.0 facility in Manchester, establishing it as a global hub for diagnostics development and Precision Medicine. This expansion supports the company's role in co-developing companion diagnostics with pharmaceutical partners. The site employs around 300 staff and will enhance hybrid and remote work options. QIAGEN has numerous FDA-approved companion diagnostic indications and collaborations with over 25 pharmaceutical firms, reinforcing its commitment to advancing Precision Medicine.

QIAGEN N.V. (NYSE: QGEN) has announced the release of its third quarter and year-to-date results scheduled for November 3, 2021. The report will be available at approximately 21:05 CET / 16:05 EDT. Following this, a conference call will occur on November 4 at 14:30 Frankfurt time where CEO Thierry Bernard and CFO Roland Sackers will discuss the results. Interested parties can access the call via multiple phone numbers, and a replay will be made available after the event.

QIAGEN has launched the QIAreach QuantiFERON-TB test, receiving CE marking to enhance global tuberculosis (TB) detection, particularly in high burden and low-resource areas. This portable device utilizes proven QuantiFERON technology to ensure reliable TB infection testing without needing extensive lab infrastructure. Clinical evaluations show high sensitivity compared to existing standards. Collaborations with distribution partners aim to facilitate affordable access across low and middle-income countries, contributing to global TB elimination targets.

QIAGEN N.V. (NYSE: QGEN) has received a $3.4 million U.S. government contract to enhance production for its NeuMoDx PCR testing systems, supporting ongoing COVID-19 testing efforts. The company aims to increase its output to over 16 million tests per year by March 2022, up from approximately 10 million. This follows a previous $600,000 contract to boost reagent production. The contracts emphasize the critical role of PCR testing in managing the pandemic and underline QIAGEN's commitment to providing essential diagnostic solutions.

QIAGEN has been selected to join the DAX index, effective September 20, 2021, marking a significant achievement as it transitions from MDAX to one of Germany's 40 largest companies by market capitalization. The company, which specializes in molecular testing, aims to deliver over $2 billion in sales in 2021. QIAGEN will also remain in the TecDAX, while reinforcing its commitment to improving health outcomes globally through its innovative Sample to Insight solutions.